Journal
Journal for Immunotherapy of Cancer
Publication Date
8-1-2022
Volume
10
Issue
8
First Page
e004761
Document Type
Open Access Publication
DOI
10.1136/jitc-2022-004761
Rights and Permissions
Fizazi K, Retz M, Petrylak DP, Goh JC, Perez-Gracia J, Lacombe L, Zschäbitz S, Burotto M, Mahammedi H, Gravis G, Bastos DA, McCune SL, Vázquez Limón JC, Kwan EM, Castellano D, Fléchon A, Saad F, Grimm MO, Shaffer DR, Armstrong AJ, Bhagavatheeswaran P, Amin NP, Ünsal-Kaçmaz K, Wang X, Li J, Loehr A, Pachynski RK. Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial. J Immunother Cancer. 2022 Aug;10(8):e004761. doi: 10.1136/jitc-2022-004761. © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. https://jitc.bmj.com/content/10/8/e004761
Recommended Citation
Fizazi, Karim; Retz, Margitta; Petrylak, Daniel P; Goh, Jeffrey C; Perez-Gracia, Jose; Lacombe, Louis; Zschäbitz, Stefanie; Burotto, Mauricio; Mahammedi, Hakim; Gravis, Gwenaelle; Bastos, Diogo Assed; McCune, Steven L; Vázquez Limón, Juan Carlos; Kwan, Edmond M; Castellano, Daniel; Fléchon, Aude; Saad, Fred; Grimm, Marc-Oliver; Shaffer, David R; Armstrong, Andrew J; Bhagavatheeswaran, Prabhu; Amin, Neha P; Ünsal-Kaçmaz, Keziban; Wang, Xuya; Li, Jun; Loehr, Andrea; and Pachynski, Russell K, "Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: Results from the phase 2 CheckMate 9KD trial." Journal for Immunotherapy of Cancer. 10, 8. e004761 (2022).
https://digitalcommons.wustl.edu/oa_4/34
